PUBLISHED DATE : Aug 2023 | Pages : 313
Fill out your details & get your free sample
The Infection Control Surveillance Solutions Market Size, Share, & Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2023–2028.
313 Pages
134 Tables
111 Charts
5 Regions
18 Countries
16 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2028) | USD 1.23 Billion |
| Market Size (2022) | USD 580.42 Million |
| CAGR (2022-2028) | 13.47% |
| Base Year | 2022 |
| Forecast Year | 2023-2028 |
| Market Segments | Solution Type, Infection Type, End-user, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY VENDORS | BD, Epic Systems, Oracle, Premier, VigiLanz, and Wolters Kluwer |
The global infection control surveillance solutions market size was valued at USD 580.42 million in 2022 and is expected to reach USD 1.23 billion by 2028, growing at a CAGR of 13.47%. Infection control surveillance solutions are tools healthcare organizations use to help prevent, detect, and control the spread of infection in their facilities. Through technology, they provide real-time data that allows healthcare providers to identify areas of risk and take preventive measures to reduce the risk of infection in their patients. The infection control surveillance solutions market has helped healthcare organizations to protect their staff, patients, and visitors and ensure the quality of care they provide. Introducing these technologies also has various benefits, such as reducing costs, improved patient outcomes, and improved safety for healthcare personnel. Furthermore, implementing these technologies is critical to maintain and comply with regulations and standards designed to defend healthcare facilities and their patients from infections and other harm.
Infection control surveillance solutions aim to identify potential infection risks within a healthcare facility. The surveillance solutions are generally comprehensive, providing early detection and disease control. Many healthcare organizations have comprehensive infectious surveillance systems to ensure the safety of their staff and patients. Furthermore, these systems can involve multiple steps, from post-infection monitoring to active management of infection by the healthcare facility. Also, it is important to ensure the surveillance system is regularly and adequately updated to achieve maximum benefit from an infection control surveillance solution.
The most common forms of infection control surveillance at healthcare facilities involve collecting and evaluating data on infectious diseases, such as types of organisms and pathogens, rate of spread, and susceptibilities. Based on these data, the healthcare facility can develop a plan to reduce and prevent the spread of infection. For example, a healthcare facility may institute limits to visitor entry, create a hazard alert system to reduce contamination in certain areas, and provide staff and patients with appropriate protective equipment. Additionally, healthcare facilities use preventative measures such as appropriate sterilization protocols, regular cleaning, and adequate screening procedures.
In some circumstances, the healthcare facility may also employ infectious control interventions, such as vaccine and antimicrobial stewardship programs. Vaccine programs involve researching and introducing vaccines to protect against dangerous pathogens. In contrast, antimicrobial stewardship programs involve optimizing antimicrobial interventions to reduce the harmful side effects of antibiotics.
The spread of infection in healthcare facilities is an ever-present threat that requires careful and consistent surveillance. In the infection control surveillance solutions market, with the help of essential tools like data collection, prevention, and intervention measures, are essential in the fight against the uncontrolled spread of disease. By actively and regularly monitoring and managing infection, healthcare facilities can ensure the safety of their staff, patients, and the community.
Growing Transformation in Hospital Safety
Growing transformation in hospital safety driving infection control surveillance solutions market is a trend in which hospitals seek to improve patient safety and reduce patient infection levels through improved surveillance solutions. This transformation began in the late 2000s with the development of various electronic medical record systems used to capture patient data more efficiently and accurately. Now, hospitals invest in more sophisticated solutions to help detect or predict infections, use evidence-based protocols to implement best practices, and track outcomes over time. These solutions are powered by data analytics, AI, ML, and predictive modeling, enabling hospitals to better and more accurately detect and mitigate infection risks. In addition to improving patient safety, these solutions can help hospitals reduce costs, improve operational efficiency, and optimize quality of care.
Advancements in Cloud-based and AI-Integrated Software for Infection Surveillance and Control
Cloud-based and AI-integrated infection surveillance and control software is an incredibly important technology that enables public health organizations to detect and respond to infections quickly and effectively. Over the years, advancements in cloud-based and AI-integrated software have greatly improved the efficacy and efficiency of infection surveillance and control. By leveraging cloud-based solutions, public health organizations can store and manage large amounts of data efficiently and securely. In addition, they can access the data in real-time, allowing for more responsive action in the face of outbreaks. Another significant advancement in cloud-based and AI-integrated infection surveillance and control software is the integration of machine learning algorithms. Machine learning algorithms enable public health organizations to generate more detailed insights from the data, enabling them to understand the underlying patterns in infections better and respond accordingly.
Growing Government Initiatives & Investment in IPC Programs Across Healthcare Settings
Infection surveillance solutions are used in healthcare settings to enable healthcare professionals to predict and prevent the spread of infectious diseases by detecting cases early, evaluating the effectiveness of interventions, and identifying tools that can be used to reduce the risk of transmission. Governments across the globe are introducing new policies and regulations that focus on developing long-term prevention programs and educating healthcare providers about the best practices for infection prevention and control. Aside from the need to maintain statistical records for the public, many governments also offer to fund healthcare centers and organizations to install more advanced software for infection surveillance. These initiatives allow organizations across healthcare facilities of different sizes to utilize state-of-the-art tools to prevent infections more efficiently, boosting the growth of the infection control surveillance solutions market.
INSIGHTS BY SOLUTION TYPE
The software solution type segment dominated the global infection control surveillance solutions market in 2022. Infection control surveillance solutions have become increasingly important tools for healthcare providers and organizations in recent years. These solutions are designed to track and prevent the spread of infection in healthcare settings and can range from simple protocols to complex software and hardware systems. On-premises infection control surveillance solutions provide healthcare providers with a comprehensive suite of infection control tools while offering the benefits of a secure, offline environment. Further, hardware-based solutions are the core of effective on-premises infection control surveillance solutions. Secure databases allow organizations to track patient data, such as infections and immunizations, in one secure and centralized location.
INSIGHTS BY INFECTION TYPE
The global infection control surveillance solutions market by infection type as bloodstream infection (BSI), urinary tract infection (UTI), pneumonia (HAP & VAP), surgical site infection (SSI), and others. The bloodstream infection (BSI) segment accounted for the largest market share, accounting for over 33% in 2022. Bloodstream infections, or bacteremia, are serious and potentially life-threatening health conditions caused by bacteria entering the bloodstream. Infectious disease surveillance is a primary infection control and surveillance solution to prevent and manage bloodstream infections. This monitoring system allows for the early detection of infection and the identification of any individual experiencing septicemia. To do this, healthcare providers must collect data regarding any patient they believe may be at risk of developing a bloodstream infection. This data includes demographic information such as age and gender and any risk factors the patient may have, such as a chronic medical condition.
INSIGHTS BY END-USER
The hospital end-user segment accounted for the largest global infection control surveillance solutions market share in 2022. Hospitals are the major sources of HAIs, and many hospitalized patients acquire pathogenic and non-pathogenic infectious during their stay. Most hospitals report CLABSI, CAUTI, SSIs, and other infections during surgical procedures and prolonged stays in ICUs. Surgical procedures include the use of invasive devices, implantation, and prosthesis. The hospital segment is dominating the global market and is witnessing steady growth in the forecasted period as hospitals & clinics are the first point of care source to get tested and treated for any disease than other healthcare settings. Infection control surveillance solutions are essential for hospitals to maintain cleanliness, compliance, and safety standards. Infection control surveillance solutions provide real-time data to give healthcare providers insight into existing and potential infection challenges and guide them in making the best decisions for their patients.
North America holds the largest global infection control surveillance solutions market share, accounting for over 34% in 2022. The large share can be attributed to the region's highly developed healthcare system and the high availability of government funds for research activities. Additionally, the region is witnessing strong investments in various aspects of the healthcare industry, including diagnosis and infection control, driving the market's growth.
Europe is the second-largest market for infection control surveillance solutions. The region’s high growth can be attributed to the availability of a well-developed healthcare system, the government initiative to promote new technologies such as ICSS in health services, and innovative technologies such as cloud computing, predictive analytics, and machine learning. Additionally, the presence of many leading market players, such as EREN (European Registry for Emerging Infectious Diseases) and Automated Healthcare Solutions, is driving the growth of the European infection control surveillance solutions market.
The competitive scenario in the global infection control surveillance solutions market is currently intensifying due to the rapidly changing technological environment. This could significantly impact vendors as customers expect continual innovations and advancements for better prevention processes. The present situation is compelling vendors to alter and redefine their products following the introduction of defined legislation to achieve a strong market presence. The market is moderately fragmented, with many international players providing various infection control surveillance solutions. The infection control surveillance solutions market is dominating, especially in the U.S., owing to many major and prominent vendors in the region.
BD, Merative, Premier, Oracle, Wolters Kluwer, and Vizilanz are the major vendors in the global infection control surveillance solutions market. All these companies have a widespread presence in major geographical regions such as North America, APAC, and Europe. However, many local vendors provide infection control surveillance solutions with similar specifications at lower prices, resulting in competition among vendors. The major vendors continuously compete for the leading position in the market, with occasional competition coming from other local vendors.
Frequently Asked Questions
How big is the infection control surveillance solutions market?
The global infection control surveillance solutions market size was valued at USD 580.42 million in 2022 and is expected to reach USD 1.23 billion by 2028.
What is the projected growth rate of the global infection control surveillance solutions market?
The global infection control surveillance solutions market is projected to grow at a CAGR of 13.47% during the forecast period.
Who are the key players in the global infection control surveillance solutions market?
BD, Epic Systems, Oracle, Premier, VigiLanz, and Wolters Kluwer are the key players in the global infection control surveillance solutions market.
What are the rising trends in the infection control surveillance solutions market?
The rising trends in the infection control surveillance solutions industry are the growing adoption of antimicrobial stewardship programs, clinical surveillance - the next step in value-based care, and advancements in cloud-based & AI-integrated infection surveillance and control software.
North America dominated the global infection control surveillance solutions market, accounting for over 34% in 2022.
The global infection control surveillance solutions market size is expected to grow at a CAGR of approximately 13.47% from 2022 to 2028.
The following factors are likely to contribute to the growth of the global infection control surveillance solutions market during the forecast period:
Base Year: 2022
Forecast Year: 2023-2028
The report considers the present scenario of the global infection control surveillance solutions market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
Key Company Profiles
Other Prominent Vendors
Segmentation by Solution Type
Segmentation by Infection Type
Segmentation by End-user
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY SOLUTION TYPE
4.3.2 MARKET SEGMENTATION BY INFECTION TYPE
4.3.3 MARKET SEGMENTATION BY END-USER
4.3.4 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 PREMIUM INSIGHTS
6.1 OVERVIEW
6.1.1 GEOGRAPHY INSIGHTS
6.1.2 SOLUTION TYPE INSIGHTS
6.1.3 INFECTION TYPE INSIGHTS
6.1.4 END-USER INSIGHTS
7 MARKET AT A GLANCE
8 INTRODUCTION
8.1 OVERVIEW
9 MARKET OPPORTUNITIES & TRENDS
9.1 GROWTH IN ADOPTION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS (ASP)
9.2 CLINICAL SURVEILLANCE IS NEXT STEP IN VALUE-BASED CARE
9.3 ADVANCES IN CLOUD-BASED AND AI-INTEGRATED SOFTWARE FOR INFECTION SURVEILLANCE AND CONTROL
10 MARKET GROWTH ENABLERS
10.1 GROWING PREVALENCE OF HOSPITAL-ACQUIRED INFECTIONS (HAI)
10.2 INCREASING NUMBER OF SURGERIES
10.3 GROWING TRANSFORMATION IN HOSPITAL SAFETY
10.4 GROWING GOVERNMENT INITIATIVES & INVESTMENT IN IPC PROGRAMS ACROSS HEALTHCARE SETTINGS
11 MARKET RESTRAINTS
11.1 HIGH DEPLOYMENT COST OF INFECTION CONTROL SURVEILLANCE SOLUTIONS
11.2 DATA SECURITY CONCERNS
11.3 RELUCTANCE TO ADOPT ADVANCED HEALTHCARE IT SOLUTIONS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET BY GEOGRAPHY
12.3.2 MARKET BY SOLUTION TYPE
12.3.3 MARKET BY INFECTION TYPE
12.3.4 MARKET BY END-USER
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 SOLUTION TYPE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 SOFTWARE
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 SERVICES
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
14 INFECTION TYPE
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 BLOOD STREAM INFECTION (BSI)
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 URINARY TRACT INFECTION (UTI)
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 PNEUMONIA (HAP & VAP)
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 SURGICAL SITE INFECTION (SSI)
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
14.7 OTHERS
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 MARKET BY GEOGRAPHY
15 END-USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 HOSPITALS
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 MARKET BY GEOGRAPHY
15.4 OUTPATIENT FACILITIES
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MARKET BY GEOGRAPHY
15.5 LONG-TERM CARE FACILITIES
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 MARKET BY GEOGRAPHY
16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW
17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.2.1 MARKET BY SOLUTION TYPE
17.2.2 MARKET BY INFECTION TYPE
17.2.3 MARKET BY END-USER
17.3 KEY COUNTRIES
17.3.1 US: MARKET SIZE & FORECAST
17.3.2 CANADA: MARKET SIZE & FORECAST
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 MARKET BY SOLUTION TYPE
18.2.2 MARKET BY INFECTION TYPE
18.2.3 MARKET BY END-USER
18.3 KEY COUNTRIES
18.3.1 GERMANY: MARKET SIZE & FORECAST
18.3.2 UK: MARKET SIZE & FORECAST
18.3.3 FRANCE: MARKET SIZE & FORECAST
18.3.4 ITALY: MARKET SIZE & FORECAST
18.3.5 SPAIN: MARKET SIZE & FORECAST
19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 MARKET BY SOLUTION TYPE
19.2.2 MARKET BY INFECTION TYPE
19.2.3 MARKET BY END-USER
19.3 KEY COUNTRIES
19.3.1 CHINA: MARKET SIZE & FORECAST
19.3.2 JAPAN: MARKET SIZE & FORECAST
19.3.3 INDIA: MARKET SIZE & FORECAST
19.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
19.3.5 AUSTRALIA: MARKET SIZE & FORECAST
20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 MARKET BY SOLUTION TYPE
20.2.2 MARKET BY INFECTION TYPE
20.2.3 MARKET BY END-USER
20.3 KEY COUNTRIES
20.3.1 BRAZIL: MARKET SIZE & FORECAST
20.3.2 MEXICO: MARKET SIZE & FORECAST
20.3.3 ARGENTINA: MARKET SIZE & FORECAST
21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 MARKET BY SOLUTION TYPE
21.2.2 MARKET BY INFECTION TYPE
21.2.3 MARKET BY END-USER
21.3 KEY COUNTRIES
21.3.1 TURKEY: MARKET SIZE & FORECAST
21.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST
21.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST
22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
22.2.1 BD
22.2.2 EPIC SYSTEMS
22.2.3 ORACLE
22.2.4 PREMIER
22.2.5 VIGILANZ
22.2.6 WOLTERS KLUWER
23 KEY COMPANY PROFILES
23.1 BD
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.1.3 KEY STRATEGIES
23.1.4 KEY STRENGTHS
23.1.5 KEY OPPORTUNITIES
23.2 EPIC SYSTEMS
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.2.3 KEY STRATEGIES
23.2.4 KEY STRENGTHS
23.2.5 KEY OPPORTUNITIES
23.3 ORACLE
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.3.3 KEY STRATEGIES
23.3.4 KEY STRENGTHS
23.3.5 KEY OPPORTUNITIES
23.4 PREMIER
23.4.1 BUSINESS OVERVIEW
23.4.2 PRODUCT OFFERINGS
23.4.3 KEY STRATEGIES
23.4.4 KEY STRENGTHS
23.4.5 KEY OPPORTUNITIES
23.5 VIGILANZ
23.5.1 BUSINESS OVERVIEW
23.5.2 PRODUCT OFFERINGS
23.5.3 KEY STRATEGIES
23.5.4 KEY STRENGTHS
23.5.5 KEY OPPORTUNITIES
23.6 WOLTERS KLUWER
23.6.1 BUSINESS OVERVIEW
23.6.2 PRODUCT OFFERINGS
23.6.3 KEY STRATEGIES
23.6.4 KEY STRENGTHS
23.6.5 KEY OPPORTUNITIES
24 OTHER PROMINENT VENDORS
24.1 BAXTER
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.2 CENTRAK
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.3 CLINISYS
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.4 HARRIS HEALTHCARE
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.5 MEDEXTER HEALTHCARE
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.6 POINTCLICKCARE
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.7 SPACELABS HEALTHCARE
24.7.1 BUSINESS OVERVIEW
24.7.2 PRODUCT OFFERINGS
24.8 VECNA TECHNOLOGIES
24.8.1 BUSINESS OVERVIEW
24.8.2 PRODUCT OFFERINGS
24.9 ECOLAB
24.9.1 BUSINESS OVERVIEW
24.9.2 PRODUCT OFFERINGS
24.10 VIZZIA TECHNOLOGIES
24.10.1 BUSINESS OVERVIEW
24.10.2 PRODUCT OFFERINGS
25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS
26 QUANTITATIVE SUMMARY
26.1 MARKET BY SOLUTION TYPE
26.1.1 NORTH AMERICA
26.1.2 EUROPE
26.1.3 APAC
26.1.4 LATIN AMERICA
26.1.5 MIDDLE EAST & AFRICA
26.2 MARKET BY INFECTION TYPE
26.2.1 NORTH AMERICA
26.2.2 EUROPE
26.2.3 APAC
26.2.4 LATIN AMERICA
26.2.5 MIDDLE EAST & AFRICA
26.3 MARKET BY END-USER
26.3.1 NORTH AMERICA
26.3.2 EUROPE
26.3.3 APAC
26.3.4 LATIN AMERICA
26.3.5 MIDDLE EAST & AFRICA
26.4 MARKET BY GEOGRAPHY
26.4.1 SOFTWARE
26.4.2 SERVICES
26.4.3 BLOOD STREAM INFECTION (BSI)
26.4.4 URINARY TRACT INFECTION (UTI)
26.4.5 PNEUMONIA (HAP & VAP)
26.4.6 SURGICAL SITE INFECTION (SSI)
26.4.7 OTHERS
26.4.8 HOSPITALS
26.4.9 OUTPATIENT FACILITIES
26.4.10 LONG-TERM CARE FACILITIES
27 APPENDIX
27.1 ABBREVIATIONS
EXHIBIT 1 SEGMENTATION OF GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
EXHIBIT 4 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
EXHIBIT 5 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
EXHIBIT 6 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
EXHIBIT 7 IMPACT OF GROWTH IN ADOPTION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS (ASP)
EXHIBIT 8 ANTIMICROBIAL STEWARDSHIP SPOTLIGHT FINDINGS IN THE US IN 2022
EXHIBIT 9 BENEFITS OF ANTIMICROBIAL STEWARDSHIP
EXHIBIT 10 IMPACT OF CLINICAL SURVEILLANCE IS NEXT STEP IN VALUE-BASED CARE
EXHIBIT 11 INSTANCES WHERE CLINICAL SURVEILLANCE SOLUTIONS ARE MOST HELPFUL
EXHIBIT 12 IMPORTANCE & TOP USE CASES OF CLINICAL SURVEILLANCE
EXHIBIT 13 CHALLENGES ADDRESSED BY CLINICAL SURVEILLANCE IN REAL TIME
EXHIBIT 14 IMPACT OF ADVANCES IN CLOUD-BASED AND AI-INTEGRATED SOFTWARE FOR INFECTION SURVEILLANCE AND CONTROL
EXHIBIT 15 IMPACT OF GROWING PREVALENCE OF HOSPITAL-ACQUIRED INFECTIONS (HAI)
EXHIBIT 16 FREQUENCY OF HAIS IN DIFFERENT WHO REGIONS AND COUNTRIES
EXHIBIT 17 IMPACT OF INCREASING NUMBER OF SURGERIES
EXHIBIT 18 IMPACT OF GROWING TRANSFORMATION IN HOSPITAL SAFETY
EXHIBIT 19 CHANGES IN HOSPITAL SAFETY PREFERENCES
EXHIBIT 20 PERCENTAGE OF RESPONDENTS WHO RANKED HAIS AND HACS AS TOP SAFETY PROBLEM IN US 2020–2022
EXHIBIT 21 IMPACT OF COVID-19 PANDEMIC ON US HOSPITAL SAFETY 2022
EXHIBIT 22 IMPACT OF GROWING GOVERNMENT INITIATIVES & INVESTMENT IN IPC PROGRAMS ACROSS HEALTHCARE SETTINGS
EXHIBIT 23 PROPORTION OF COUNTRIES MEETING IPC MINIMUM REQUIREMENTS BY LEVEL OF INCOME CLASSIFIED BY WORLD BANK GROUP
EXHIBIT 24 IMPACT OF HIGH DEPLOYMENT COST OF INFECTION CONTROL SURVEILLANCE SOLUTIONS
EXHIBIT 25 IMPACT OF DATA SECURITY CONCERNS
EXHIBIT 26 IMPACT OF RELUCTANCE TO ADOPT ADVANCED HEALTHCARE IT SOLUTIONS
EXHIBIT 27 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 28 OVERVIEW OF GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022 & 2028
EXHIBIT 29 OVERVIEW OF GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022 & 2028
EXHIBIT 30 OVERVIEW OF GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022 & 2028
EXHIBIT 31 OVERVIEW OF GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022 & 2028
EXHIBIT 32 FIVE FORCES ANALYSIS 2022
EXHIBIT 33 INCREMENTAL GROWTH BY SOLUTION TYPE 2022 & 2028
EXHIBIT 34 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 35 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 36 GLOBAL SOFTWARE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL SOFTWARE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 38 GLOBAL SERVICES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL SERVICES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 40 INCREMENTAL GROWTH BY INFECTION TYPE 2022 & 2028
EXHIBIT 41 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 42 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 43 GLOBAL BLOOD STREAM INFECTION (BSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL BLOOD STREAM INFECTION (BSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 45 GLOBAL URINARY TRACT INFECTION (UTI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 46 GLOBAL URINARY TRACT INFECTION (UTI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 47 GLOBAL PNEUMONIA (HAP & VAP) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL PNEUMONIA (HAP & VAP) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 49 GLOBAL SURGICAL SITE INFECTION (SSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL SURGICAL SITE INFECTION (SSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 51 GLOBAL OTHERS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL OTHERS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 53 INCREMENTAL GROWTH BY END-USER 2022 & 2028
EXHIBIT 54 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 55 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER: ABSOLUTE GROWTH (%)
EXHIBIT 56 GLOBAL HOSPITALS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 GLOBAL HOSPITALS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 58 GLOBAL OUTPATIENT FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL OUTPATIENT FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 60 GLOBAL LONG-TERM CARE FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 GLOBAL LONG-TERM CARE FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 62 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028
EXHIBIT 63 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 64 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
EXHIBIT 65 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: KEY COUNTRIES 2022 ($ MILLION)
EXHIBIT 66 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 67 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 68 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028
EXHIBIT 69 US INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 70 CANADA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 71 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: KEY COUNTRIES 2022 ($ MILLION)
EXHIBIT 72 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 74 INCREMENTAL GROWTH IN EUROPE 2022 & 2028
EXHIBIT 75 GERMANY INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 76 UK INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 77 FRANCE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 78 ITALY INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 79 SPAIN INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 80 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: KEY COUNTRIES 2022 ($ MILLION)
EXHIBIT 81 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 82 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 83 INCREMENTAL GROWTH IN APAC 2022 & 2028
EXHIBIT 84 CHINA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 85 JAPAN INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 86 INDIA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 87 SOUTH KOREA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 88 AUSTRALIA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 89 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: KEY COUNTRIES 2022 ($ MILLION)
EXHIBIT 90 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 91 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 92 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028
EXHIBIT 93 BRAZIL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 94 MEXICO INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 95 ARGENTINA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 96 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: KEY COUNTRIES 2022 ($ MILLION)
EXHIBIT 97 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 98 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 99 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028
EXHIBIT 100 TURKEY INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 101 SOUTH AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 102 SAUDI ARABIA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET 2022–2028 ($ MILLION)
EXHIBIT 103 MARKET DOMINANCE ANALYSIS OF VENDORS OFFERING INFECTION CONTROL SURVEILLANCE SOLUTIONS
EXHIBIT 104 CAPABILITIES & EXPERTISE ASSESSMENT OF VENDORS OFFERING COMMERCIAL INFECTION CONTROL SURVEILLANCE SOLUTIONS
EXHIBIT 105 BD: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 106 BD: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 107 BD: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 108 BD: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 109 PREMIER: TOTAL REVENUE 2020–2022 ($ MILLION)
EXHIBIT 110 PREMIER: R&D EXPENDITURE 2020–2022 ($ MILLION)
EXHIBIT 111 WOLTERS KLUWER: TOTAL REVENUE 2020–2022 ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2016–2022
TABLE 3 EXPERIENCES OF USERS OF SEMI-AUTOMATED OR FULLY-AUTOMATED SURVEILLANCE SYSTEMS AT SURVEILLANCE NETWORK AND HOSPITAL LEVEL
TABLE 4 AVERAGE VOLUME OF SURGERY CONDUCTED ANNUALLY ACCORDING TO HUMAN DEVELOPMENT INDEX (HDI)
TABLE 5 COUNTRYWIDE DATA ON SURGICAL PROCEDURES AND HOSPITALIZATION RATE (PER 100,000)
TABLE 6 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022 & 2028 ($ MILLION)
TABLE 7 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022 & 2028 ($ MILLION)
TABLE 8 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022 & 2028 ($ MILLION)
TABLE 9 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022 & 2028 ($ MILLION)
TABLE 10 GLOBAL SOFTWARE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 11 GLOBAL SOFTWARE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 12 GLOBAL SERVICES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 13 GLOBAL SERVICES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 14 GLOBAL BLOOD STREAM INFECTION (BSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 15 GLOBAL BLOOD STREAM INFECTION (BSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 16 GLOBAL URINARY TRACT ) INFECTION (UTI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 17 GLOBAL URINARY TRACT ) INFECTION (UTI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 18 GLOBAL PNEUMONIA (HAP & VAP) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 19 GLOBAL PNEUMONIA (HAP & VAP) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 20 GLOBAL SURGICAL SITE INFECTION (SSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 21 GLOBAL SURGICAL SITE INFECTION (SSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 22 GLOBAL OTHERS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 23 GLOBAL OTHERS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 24 GLOBAL HOSPITALS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 25 GLOBAL HOSPITALS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 26 GLOBAL OUTPATIENT FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 27 GLOBAL OUTPATIENT FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 28 GLOBAL LONG-TERM CARE FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 29 GLOBAL LONG-TERM CARE FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 30 COUNTRYWIDE HEALTHCARE-ASSOCIATED INFECTIONS RATE (%)
TABLE 31 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 32 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 33 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 34 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 35 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 36 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 37 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 38 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 39 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 40 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 41 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 42 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 43 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 44 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 45 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 46 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 47 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 48 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 49 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 50 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 51 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 52 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 53 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 54 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 55 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 56 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 57 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 58 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 59 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 60 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 61 BD: MAJOR PRODUCT OFFERINGS
TABLE 62 EPIC SYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 63 ORACLE: MAJOR PRODUCT OFFERINGS
TABLE 64 PREMIER: MAJOR PRODUCT OFFERINGS
TABLE 65 VIGILANZ: MAJOR PRODUCT OFFERINGS
TABLE 66 WOLTERS KLUWER: MAJOR PRODUCT OFFERINGS
TABLE 67 BAXTER: MAJOR PRODUCT OFFERINGS
TABLE 68 CENTRAK: MAJOR PRODUCT OFFERINGS
TABLE 69 CLINISYS: MAJOR PRODUCT OFFERINGS
TABLE 70 HARRIS HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 71 MEDEXTER HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 72 POINTCLICKCARE: MAJOR PRODUCT OFFERINGS
TABLE 73 SPACELABS HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 74 VECNA TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 75 ECOLAB: MAJOR PRODUCT OFFERINGS
TABLE 76 VIZZIA TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 77 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 78 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 79 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 80 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 81 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 82 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 83 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 84 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 85 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 86 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 87 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 ($ MILLION)
TABLE 88 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY SOLUTION TYPE 2022–2028 (%)
TABLE 89 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 90 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 91 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 92 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 93 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 94 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 95 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 96 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 97 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 98 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 99 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 ($ MILLION)
TABLE 100 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY INFECTION TYPE 2022–2028 (%)
TABLE 101 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 102 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 103 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 104 NORTH AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 105 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 106 EUROPE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 107 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 108 APAC INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 109 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 110 LATIN AMERICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 111 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 ($ MILLION)
TABLE 112 MIDDLE EAST & AFRICA INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY END-USER 2022–2028 (%)
TABLE 113 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 114 GLOBAL INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 115 GLOBAL SOFTWARE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 116 GLOBAL SOFTWARE INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 117 GLOBAL SERVICES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 118 GLOBAL SERVICES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 119 GLOBAL BLOOD STREAM INFECTION (BSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 120 GLOBAL BLOOD STREAM INFECTION (BSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 121 GLOBAL URINARY TRACT INFECTION (UTI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 122 GLOBAL URINARY TRACT INFECTION (UTI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 123 GLOBAL PNEUMONIA (HAP & VAP) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 124 GLOBAL PNEUMONIA (HAP & VAP) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 125 GLOBAL SURGICAL SITE INFECTION (SSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 126 GLOBAL SURGICAL SITE INFECTION (SSI) INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 127 GLOBAL OTHERS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 128 GLOBAL OTHERS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 129 GLOBAL HOSPITALS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 130 GLOBAL HOSPITALS INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 131 GLOBAL OUTPATIENT FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 132 GLOBAL OUTPATIENT FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 133 GLOBAL LONG-TERM CARE FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 ($ MILLION)
TABLE 134 GLOBAL LONG-TERM CARE FACILITIES INFECTION CONTROL SURVEILLANCE SOLUTIONS MARKET BY GEOGRAPHY 2022–2028 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
